GSK Archives - Page 6 of 6 - Medical Design Sourcing

Late last year, GlaxoSmithKline (NYSE:GSK) and Sanofi (NYSE:SNY) announced that their joint COVID-19 vaccine was delayed.

Now, GlaxoSmithKline is hooking up with Germany-headquartered CureVac (NSDQ:CVAC) to develop a COVID-19 vaccine that can target multiple variants of the virus simultaneously. GSK plans on spending €150 million on the project, paying the first half to CureVac initially and the latter half as a milestone payment.

For GSK, the project also entails a shift in viral platform. Its previous vaccine candidate was an adjuvanted recombinant protein-based COVID-19 vaccine.

The new project, however, will use the mRNA platform that Moderna (NSDQ:MRNA) and Pfizer (NYSE:PFE) have deployed in their vaccines, which were the first to win FDA authorization in the U.S.

The two companies plan to commercially launch an mRNA vaccine in 2022, pending regulatory approval.

GSK will also work with CureVac to produce up to 100 million doses of its …

CRISPR startup Mammoth Biosciences will partner with GlaxoSmithKline’s (NYSE:GSK) consumer healthcare division to develop a home-based diagnostic capable of detecting active SARS-CoV-2, the novel coronavirus that causes COVID-19.

The collaboration will use Mammoth Biosciences’ CRISPR-based Detectr platform to design “guide-RNA” that can identify and signal the presence of viral strands obtained through a simple nasal swab, according to Mammoth Biosciences CEO Trevor Martin.

Martin said he couldn’t speak to the specifics of the deal with GSK.

“This is really a long-term play in the next generation of diagnostics,” he said in an interview with MassDevice. “One of the powers of the CRISPR-based platform is you can switch out the guide-DNA, so over the long term you can imagine using the same platform for a variety of diseases.”

The company intends to file for an FDA emergency use authorization for the test by the end of 2020. If it’s app…

GSK

GSK and CureVac team up on COVID-19 vaccine to battle viral variants

Mammoth deal with GSK could lead to home COVID-19 test